Cytokine gene polymorphisms in psoriasis

Craven, N. M.; Jackson, C. P.; Kirby, Brian; Perrey, Chris; Pravica, Vera; Hutchinson, Ian V.; Griffiths, C.E.M.

doi:10.1046/j.1365-2133.2001.04143.x

Cited by 79 publications

(78 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic AD skin lesions have significantly fewer Th2 cytokine-, but greater numbers of Th1 cytokine-expressing cells, than in acute AD [8] . Psoriasis patients exhibit a Th1 bias in the lesion skin and in the peripheral blood, and are thought to develop Th1 cytokine networks [13] . Indeed, tacrolimus hydrate (tacrolimus), a potent immunosuppressant that is currently used topically in the treatment of AD and psoriasis, suppressed the cutaneous inflammation in this model.…”

Section: Introductionmentioning

confidence: 99%

Olopatadine Ameliorates Rat Experimental Cutaneous Inflammation by Improving Skin Barrier Function

et al. 2007

View full text Add to dashboard Cite

Olopatadine hydrochloride (olopatadine) is an antiallergic agent with histamine H₁ receptor antagonistic action. We investigated the possible efficacies of olopatadine on the chronic inflammatory dermatitis and the impaired skin barrier functions induced by repeated application of oxazolone in rats. Oxazolone-sensitized rats were challenged with oxazolone applied to the ear every 3 days. Olopatadine was orally administered once daily (1 and 3 mg/kg/day). The effects of the drug were quantified by measurements of ear thickness, levels of cytokines in the lesioned ear and the number of scratching episodes. As parameters of skin barrier function, transepidermal water loss (TEWL) and hyaluronic acid (HA) levels in the lesioned ear were measured. The effect of olopatadine on the production of HA by cultured dermal fibroblasts was also measured. Repeated topical application of oxazolone to rat ears induced local inflammation that was exemplified by swelling. In inflamed ears, the amount of IFNγ increased at both the protein and mRNA level, but IL-4 levels changed minimally. Olopatadine significantly decreased ear swelling and the number of scratching episodes. The drug also significantly inhibited the increase of IFNγ and nerve growth factor production in inflamed ears. Olopatadine significantly inhibited the increase in TEWL and the decrease in HA in lesioned ears. Furthermore, the drug stimulated the production of HA by cultured dermal fibroblasts. These results suggest that olopatadine suppressed inflammation and scratching not only by inhibiting cytokine production, but also by repairing skin barrier function.

show abstract

Section: Introductionmentioning

confidence: 99%

Olopatadine Ameliorates Rat Experimental Cutaneous Inflammation by Improving Skin Barrier Function

et al. 2007

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15] A number of studies have been presented providing evidence for associations between these IL-10 promoter variants and infectious or autoimmune diseases, including meningococcal infection, fatal septicemia, systemic lupus erythematodes, reactive arthritis, psoriasis, Sjogreń s syndrome, and multiple sclerosis. 10,12,[16][17][18][19][20] So far, it has not been studied, however, whether IL-10 promoter variants influence lymphocyte proliferation upon antigen stimulation, a major regulatory function attributed to IL-10.…”

Section: Introductionmentioning

confidence: 99%

Promoter haplotypes of the interleukin-10 gene influence proliferation of peripheral blood cells in response to helminth antigen

et al. 2004

View full text Add to dashboard Cite

Since interleukin (IL)-10 is a key mediator of immunosuppression, and immunosuppression is considered an important element of helminth infection, we studied variants of the putative IL-10 gene promoter in 337 individuals from 130 families heavily exposed to infection by the tissue nematode Onchocerca volvulus. As shown by transmission disequilibrium tests, variants of the IL-10 promoter at positions -1082(G/A), -819(C/T), and -592(C/A) in the haplotype of ATA were significantly associated with high peripheral blood cell (PBC) proliferative responses to O. volvulus antigen (OvAg). No associations were observed using phytohemagglutinin-induced PBC proliferation or with qualitative or quantitative phenotypes of onchocerciasis or onchocerciasis-related skin disease. The findings are compatible with the hypothesis that the ATA haplotype causes a decrease in IL-10 production by OvAg-reactive type-1 regulatory T-lymphocytes, thereby alleviating the suppression of other T cells. To our knowledge, this is the first time that an influence of IL-10 promoter variants is shown on the adaptive immune response.

show abstract

“…[11][12][13] Up to now only few studies have showed an association between IL-10 promoter SNPs and the susceptibility to psoriasis. 14,15 In the light of the above findings, the aim of this study was to determine the distribution of the IL-10 5 0 flanking region haplotypes in psoriasis patients and in healthy controls, and to investigate whether polymorphisms at IL-10 promoter region influence susceptibility to and/or severity in this chronic skin disease.…”

mentioning

confidence: 99%

IL-10 promoter polymorphisms influence disease severity and course in psoriasis

et al. 2003

View full text Add to dashboard Cite

We analyzed three single-nucleotide polymorphisms (SNPs) at the interleukin-10 (IL-10) 5 0 flanking region (positions À1082 A/ G, À819 C/T and À592 C/A) in an association case-control study involving 248 patients with plaque type of psoriasis and 148 unrelated healthy volunteers using ARMS (amplification refractory mutation system)-PCR (Polymerase Chain Reaction) method. No difference was found in the frequencies of haplotype distribution between healthy controls and patients with psoriasis. There were no significant differences in the IL-10 haplotype distribution depending on the age of onset and family history of psoriasis. However, the results of our study demonstrate that the IL-10 haplotype has a role in determining severity and course of plaque type of psoriasis. IL-10 ACC haplotype (Po0.05) is likely to be defining lower activity of disease (PASIr20; extentr10%) and ATA haplotype is likely to be associated with persistent eruption (Po0.01). As ACC haplotype is suggested to be associated with high IL-10 secretion and ATA is related to low IL-10 secretion, potential differences in the IL-10 secretion levels might contribute the differences in the clinical course of psoriasis.

show abstract

Cytokine gene polymorphisms in psoriasis

Abstract: Psoriasis is not determined by a genotype consistent with high production of Th1 cytokines or low production of Th2 cytokines. Thus, the Th1 cytokine profile found in psoriatic plaques is most likely a consequence of local factors.

Cited by 79 publications

References 39 publications

Olopatadine Ameliorates Rat Experimental Cutaneous Inflammation by Improving Skin Barrier Function

Olopatadine Ameliorates Rat Experimental Cutaneous Inflammation by Improving Skin Barrier Function

Promoter haplotypes of the interleukin-10 gene influence proliferation of peripheral blood cells in response to helminth antigen

IL-10 promoter polymorphisms influence disease severity and course in psoriasis

Contact Info

Product

Resources

About